Real-time Estimate Cboe BZX 10:24:04 06/05/2024 pm IST 5-day change 1st Jan Change
92.18 USD -0.58% Intraday chart for BioNTech SE +4.81% -12.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Dpa-AFX Overview: COMPANIES from 06.05.2024 - 15:15 DP
Sector Update: Health Care Stocks Gain Pre-Bell Monday MT
Sector Update: Health Care MT
Transcript : BioNTech SE, Q1 2024 Earnings Call, May 06, 2024
BioNTech Swings to Net Loss on Lower Covid Vaccine Sales DJ
BioNTech Swings to Q1 Loss, Revenue Falls -- Shares Decline Pre-Bell MT
Futures Rise Pre-Bell Ahead of Latest Earnings Week; Asia Mostly Up, Europe Strong MT
Inflation, Interest Rate Outlooks Lift Wall Street Pre-Bell; Asia, Europe Up MT
BioNTech says 90% of 2024 revenues will accrue at end of year RE
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return DJ
News Highlights : Top Global Markets News of the Day - Monday at 5 AM ET DJ
News Highlights : Top Global Markets News of the Day - Monday at 3 AM ET DJ
News Highlights : Top Global Markets News of the Day - Monday at 1 AM ET DJ
News Highlights : Top Global Markets News of the Day - Sunday at 11 PM ET DJ
News Highlights : Top Global Markets News of the Day - Sunday at 9 PM ET DJ
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
Sector Update: Health Care Stocks Drop in Afternoon Trading MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines MT
GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines MT
GSK Files Lawsuit Against Pfizer, BioNTech Over mRNA Patents Infringement MT
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology RE
Scholz promises support for pharma sector in Germany as Merck invests RE
BIONTECH : Gets a Neutral rating from Deutsche Bank ZD
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... Our Logo
Market outlook is uncertain, but optimism prevails Our Logo
Chart BioNTech SE
More charts
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
86.07 EUR
Average target price
107 EUR
Spread / Average Target
+24.34%
Consensus
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. News BioNTech SE
  5. BioNTech Plans 50% Workforce Boost, $57 Million Investment At German Factory
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW